Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
Phathom Pharmaceuticals, Inc. (PHAT) to report Q4 and full year 2023 financial results and business progress on March 7, 2024.
02/29/2024 - 08:00 AM
Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET FLORHAM PARK, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 7, 2024, to report its fourth quarter and full year 2023 financial results and provide recent business progress.
A live webcast and additional information about the presentation can be accessed on News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations . Participants can register for the call here . Recordings will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc. H. pylori infection in adults. For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and X .
MEDIA CONTACT media@phathompharma.com
INVESTOR CONTACT ir@phathompharma.com
© 2024 Phathom Pharmaceuticals. All rights reserved.
When will Phathom Pharmaceuticals, Inc. report its Q4 and full year 2023 financial results?
Phathom Pharmaceuticals, Inc. will report its Q4 and full year 2023 financial results on March 7, 2024.
What time will the live webcast for Phathom Pharmaceuticals, Inc. financial results be held on March 7, 2024?
The live webcast for Phathom Pharmaceuticals, Inc. financial results will be held at 8:30 am ET on March 7, 2024.
What is Phathom Pharmaceuticals, Inc.'s ticker symbol?
Phathom Pharmaceuticals, Inc.'s ticker symbol is PHAT.
Phathom Pharmaceuticals Inc
PHAT Rankings
#3223 Ranked by Stock Gains
PHAT Stock Data
Industry
Medicinal and Botanical Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Manufacturing, Medicinal and Botanical Manufacturing
About PHAT
phathom pharmaceuticals, inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. the company has the rights in the united states, europe, and canada to vonoprazan, a potassium-competitive acid blocker (p-cab) that blocks acid secretion in the stomach. it is also developing vonoprazan, which is in phase iii clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of helicobacter pylori infection. the company was incorporated in 2018 and is based in buffalo grove, illinois.
